Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck & Co Receives Updated Ratings With Price Targets Between $155 and $175

Guavy AI Editorial Team
Instruments
GS MRK
Share

Merck & Co (MRK.US) has received updated ratings from major Wall Street analysts, with price targets ranging from $155 to $175.

The updates come on August 21, as Goldman Sachs analyst Asad Haider maintains a buy rating and keeps the target price at $160. UBS analyst Michael Yee also maintains a buy rating but adjusts the target price from $145 to $175.

BMO Capital analyst Evan Seigerman and Scotiabank analyst Louise Chen maintain their buy ratings with adjusted target prices of $170 and $155, respectively.

More on Stocks

Stocks just now

Boeing 787's Unique Landing Gear System: Early Doors Function

Stocks just now

Moderna Soars on Cancer Breakthrough, But Analysts Warn of Patience Required

Stocks just now

Merck Stock Hits Record High After Cancer Vaccine Breakthrough

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy